The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas

01 Jan 2005

Bayer's retreat from the global, primary-care stage into the mid-sized, regionally-focused specialist player arena was forced upon it by its own particular set of challenges. But other drug firms facing similar issues should take note: globalism may not be the best way forward in today's environment.

By Melanie Senior

Globalization has long been the buzzword among drug firms—not just among Big Pharma, but also among mid-sized firms seeking new...